BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia

Leukemia and Lymphoma

Volumn 42, Issue 5, 2001, Pages 871-880

  Clark, R E ^a   Christmas, S E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

BCR ABL; CML; Cytotoxic T lymphocytes; Helper T lymphocytes; HLA; Peptides

Indexed keywords

BCR ABL PROTEIN; GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

CHRONIC MYELOID LEUKEMIA; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

EID: 0034856371     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097706     Document Type: Review

References (78)

1. A minute chromosome in human chronic granulocytic leukemia
2. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa sta ining
3. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
4. 1 translocation
5. Phase II study of STI 571, a tyrosine kinase inhibitor in patients (pts) with resistant or refractory Philadelphia chromosome positive chronic myeloid leukemia
6. A phase II study of STI 571 in adult patients with philadelphia chromosome positive chronic myeloid leukaemia in accelerated phase
7. T-cell depletion of HLA-identical transplants in leukemia
8. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
9. The molecular genetics of philadelphia chromosome-positive leukemias
10. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
11. The biology of chronic myeloid leukemia
12. The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukaemia
13. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene
14. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: No correlation with clinical features, cytogenetic response, duration of chronic phase, or survival
15. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukaemia
16. Molecular abnormalities of bcr and c-abl in chronic myelogenous leukaemia associated with a long chronic phase
17. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia
18. Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical states and prognosis of the disease
19. Neutrophilic chronic myeloid leukemia: A distinct disease with a specific molecular marker
20. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia
21. The bcr-abl gene in chronic myelogenous leukemia
22. Chronic myelogenous leukemia: From pathogenesis to therapy
23. Cellular and molecular mechanisms in chronic myeloid leukaemia: Biology and treatment
24. The molecular biology of chronic myeloid leukemia
25. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
26. A new foreign policy: MHC Class I molecules monitor the outside world
27. Gene fusions encoding chimaeric transcription factors in solid tumours
28. Defined antigens recognized by T lymphocytes on human tumours
29. Specific binding of leukemia oncogene fusion protein peptides to HLA Class I molecules
30. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes
31. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes
32. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules
33. BCR-ABL directed immunotherapy: A virtual reality?
34. Synthetic analogue BCR-ABL fusion peptides improve Class I immunogenicity to the native protein
35. Cytotoxic T-cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia
36. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: Studies in antigen-processing defective cell lines
37. ABL-BCR mRNAs transcribed from chromosome 9q+ in Philadelphia-chromosome-positive chronic myeloid leukaemia
38. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia
39. T lymphocytes in chronic myelogenous leukaemia (CML): No evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridisation in 14 patients
40. Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia
41. Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes
42. Antibody recognition of the tumour-specific bcr-abl joining region in chronic myeloid leukaemia
43. T-cell immunity to the joining region of p210 BCR-ABL protein
44. Immune responses to chronic myeloid leukaemia
45. 1- cells from the same patient
46. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions
47. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation
48. Specific human cellular immunity to bcr-abl oncogene-derived peptides
49. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients
50. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukaemic cells from patients with chronic myeloid leukaemia
51. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct
52. The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity
53. Immunological characterisation of the tumour specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukaemia
54. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide
55. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates
56. + cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR restricted manner
57. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients
58. BCR-ABL protein by human T cells
59. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
60. BCR/ABL leukaemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognised by T cells found at low frequency in the repertoire of normal donors
61. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukaemia using modifications of a limiting dilution assay
62. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in Chronic Myeloid Leukaemia
63. T cells from patients with chronic myeloid leukaemia have the ability to kill both autologous and HLA-matched leukaemic cells
64. Direct evidence that chronic myeloid leukaemia (CML) cells can express BCR-ABL junctional oligopeptides in association with class I HLA
65. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
66. Spontaneous remission in a patient with chronic myeloid leukaemia
67. Spontaneous remission of chronic myeloid leukaemia with loss of the Philadelphia chromosome British
68. Spontaneous remission in a patient with chronic myelogenous leukemia
69. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukaemia
70. Use of leukaemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukaemia
71. Vaccination of patients with chronic myelogenous leukaemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
72. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukaemia
73. The HLA class I-CML association revisited taking into account the two forms of gene fusion in the Philadelphia chromosome. A multicenter study
74. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules
75. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: Implications for vaccine development
76. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
77. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
78. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1